BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38613350)

  • 21. Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients.
    Jiang ZR; Yang LH; Jin LZ; Yi LM; Bing PP; Zhou J; Yang JS
    Front Oncol; 2022; 12():988680. PubMed ID: 36203428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
    Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
    Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
    Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
    Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of cuproptosis -related subtypes, the development of a prognosis model, and characterization of tumor microenvironment infiltration in prostate cancer.
    Jin L; Mei W; Liu X; Sun X; Xin S; Zhou Z; Zhang J; Zhang B; Chen P; Cai M; Ye L
    Front Immunol; 2022; 13():974034. PubMed ID: 36203594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma.
    Sang C; Yan L; Lin J; Lin Y; Gao Q; Shen X
    J Cancer Res Clin Oncol; 2024 Apr; 150(4):199. PubMed ID: 38627278
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Construction and validation of a cuproptosis-related lncRNA signature as a novel and robust prognostic model for colon adenocarcinoma.
    Xu M; Mu J; Wang J; Zhou Q; Wang J
    Front Oncol; 2022; 12():961213. PubMed ID: 35965536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
    Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
    Front Immunol; 2022; 13():991604. PubMed ID: 36685508
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer.
    Huang Y; Yin D; Wu L
    Sci Rep; 2022 Oct; 12(1):17348. PubMed ID: 36253436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cuproptosis-related gene SERPINE1 is a prognostic biomarker and correlated with immune infiltrates in gastric cancer.
    Feng L; Li G; Li D; Duan G; Liu J
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):10851-10865. PubMed ID: 37318594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cuproptosis illustrates tumor micro-environment features and predicts prostate cancer therapeutic sensitivity and prognosis.
    Cheng B; Tang C; Xie J; Zhou Q; Luo T; Wang Q; Huang H
    Life Sci; 2023 Jul; 325():121659. PubMed ID: 37011878
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
    Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
    Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
    Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
    Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer.
    Li W; Zhang X; Chen Y; Pang D
    Front Oncol; 2022; 12():966511. PubMed ID: 36212436
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in colon adenocarcinoma.
    Wang J; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Qin D; Zhong S; Hu X
    Front Oncol; 2023; 13():1152681. PubMed ID: 37333810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development and validation of cuproptosis molecular subtype-related signature for predicting immune prognostic characterization in gliomas.
    Huang H; Lv Z; Yang L; Zhang X; Deng Y; Huang Z; Bi H; Sun X; Zhang M; Hu D; Liang H; Hu F
    J Cancer Res Clin Oncol; 2023 Oct; 149(13):11499-11515. PubMed ID: 37392200
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive investigation into cuproptosis in the characterization of clinical features, molecular characteristics, and immune situations of clear cell renal cell carcinoma.
    Wang B; Song Q; Wei Y; Wu X; Han T; Bu H; Tang S; Qian J; Shao P
    Front Immunol; 2022; 13():948042. PubMed ID: 36275737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cuproptosis-related modification patterns depict the tumor microenvironment, precision immunotherapy, and prognosis of kidney renal clear cell carcinoma.
    Cai Z; He Y; Yu Z; Hu J; Xiao Z; Zu X; Li Z; Li H
    Front Immunol; 2022; 13():933241. PubMed ID: 36211378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The cuproptosis-related signature associated with the tumor environment and prognosis of patients with glioma.
    Wang W; Lu Z; Wang M; Liu Z; Wu B; Yang C; Huan H; Gong P
    Front Immunol; 2022; 13():998236. PubMed ID: 36110851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma.
    Feng J; Wang J; Xu Y; Lu F; Zhang J; Han X; Zhang C; Wang G
    PLoS One; 2023; 18(7):e0288180. PubMed ID: 37405988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The signature of cuproptosis-related immune genes predicts the tumor microenvironment and prognosis of prostate adenocarcinoma.
    Yao K; Zhang R; Li L; Liu M; Feng S; Yan H; Zhang Z; Xie D
    Front Immunol; 2023; 14():1181370. PubMed ID: 37600770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.